Skip to main content
. 2021 Mar 18;18(4):1491–1506. doi: 10.1021/acs.molpharmaceut.0c01238

Figure 4.

Figure 4

Main strategies for central nervous system delivery of antisense oligonucleotides (ASOs) and small interfering RNA (siRNA). Unformulated/naked and chemical modifications predominate for ASOs, while conjugates and nanocarrier systems have been more widely studied for siRNA.